Article Details

Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis

Retrieved on: 2021-03-23 12:22:30

Tags for this article:

Click the tags to see associated articles and topics

Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis. View article details on hiswai:

Excerpt

... disease of the central nervous system, in which the immune system attacks the ... Anokion SA is a Swiss biotechnology company that aims to make a ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo